Ultromics is a global health technology company which provides autonomous echocardiography analysis through innovative AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease.
Our cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. Our aim is to save clinicians time and allow them to confidently make diagnostic decisions. We are helping healthcare providers streamline care, increase productivity and improve patient outcomes whilst also allowing them to make valuable resource and cost savings.
For more information about Ultromics visit http://www.ultromics.com/
Our cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. Our aim is to save clinicians time and allow them to confidently make diagnostic decisions. We are helping healthcare providers streamline care, increase productivity and improve patient outcomes whilst also allowing them to make valuable resource and cost savings.
For more information about Ultromics visit http://www.ultromics.com/
Location: United Kingdom
Employees: 51-200
Total raised: $112.58M
Founded date: 2017
Investors 6
| Date | Name | Website |
| 08.09.2021 | Optum Vent... | optumventu... |
| - | Oxford Uni... | innovation... |
| - | NovaCapita... | novacapita... |
| - | Oxford Sci... | oxfordscie... |
| 22.10.2021 | GV | gv.com |
| 16.11.2021 | Blue Ventu... | blueventur... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 31.07.2025 | Series C | $56.14M | Allegis Ca... |
| 16.08.2021 | Series B | $33M | - |
| 17.06.2020 | - | $10M | - |
| 22.05.2018 | Series A | $13.44M | - |
Mentions in press and media 30
| Date | Title | Description |
| 09.03.2026 | Advancing cardiovascular health – SignaCor Therapeutics lands €288k investment as pat of €1.1 million Seed round | Darach Neeson, CEO at SignaCor, says: “The Spark programme’s content was exceptional – value-filled insights from UK life science industry experts and meaningful investor engagement. The lessons learned have influenced our strategy, and we ... |
| 17.02.2026 | French HealthTech Innovator Lifeaz Secures €13M for Defibrillator Democratization | Lifeaz, a French HealthTech firm, raised €13 million. The funding aims to democratize defibrillator access. It targets both homes and businesses. The company plans to save 1,000 lives in five years. European expansion is a key objective. Li... |
| 12.02.2026 | Paris-based Lifeaz raises €13 million to democratise defibrillator access and save 1000 lives within five years | Lifeaz, a Paris-based startup specialising in the democratisation of defibrillators for individuals and businesses, today announced that it has raised €13 million in funding to accelerate its growth and prepare its European rollout. Existin... |
| 06.10.2025 | NanoPhoria closes €83.5 million Series A for its heart failure candidate – one of Italy’s largest 2025 BioTech rounds | Milan-based NanoPhoria Bioscience today announced the successful first close of its €83.5 million Series A financing round – the largest ever Series A round in Italian BioTech history – for its lung-to-heart drug delivery platform. The roun... |
| 11.09.2025 | UK’s top tech scale-ups named, but can Britain keep hold of them? | Tech Nation has announced its Future Fifty 2025 cohort, featuring 25 high-growth UK scaleups across various sectors, including AI, climatetech, healthtech, and spacetech. Between them, these firms have raised more than £1.4bn and employ ove... |
| 31.07.2025 | Ultromics Secures $55M to Revolutionize Heart Disease Diagnosis with AI | Ultromics, a leader in AI-driven cardiology, secured $55 million in Series C funding. This significant investment propels its mission to transform heart disease diagnosis. The company's EchoGo® platform utilizes advanced AI. It analyzes sta... |
| 31.07.2025 | Ultromics Secures $55M to Expand AI-Driven Cardiology Solutions for Heart Failure | What You Should Know: – Ultromics, a pioneer in AI-driven cardiology solutions secures $55M in Series C financing co-led by L&G, Allegis Capital, and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fu... |
| 31.07.2025 | Ultromics raises $55M Series C to scale AI-driven heart failure detection | Oxford-based Ultromics, a pioneer in AI-driven cardiology diagnostics solutions, has raised $55 million through its Series C funding round. Ultromics has developed the first FDA-cleared, Medicare-reimbursed AI technology designed to help cl... |
| 31.07.2025 | Ultromics Raises $55M in Series C Funding | Ultromics, an Oxford, UK-based company which specializes in AI-driven cardiology solutions, raised $55M in Series C funding. The round was led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises... |
| 31.07.2025 | Ultromics: $55 Milloin Series C Raised For AI-Based Cardiology Solutions | Ultromics, a leader in AI-driven cardiology solutions, has raised $55 million in Series C financing. This funding round was co-led by L&G, Allegis Capital, and Lightrock, with additional support from organizations like Oxford Science En... |
Show more